Navicare Biotech Co (ROCO:8472) Accounts Payable: NT$247.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8472 Navicare Biotech Co Ltd ROCO:8472
56 GF Score
Price NT$68.20
GF Value NT$44.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Navicare Biotech Co Accounts Payable?

Navicare Biotech Co ROCO:8472 -1.30% 56 Accounts Payable is NT$247.8 Mil as of Dec. 2025. GuruFocus rates ROCO:8472 with a GF Score™ of 56/100 and a GF Value™ of NT$44.45 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Navicare Biotech Co's Accounts Payable for the quarter that ended in Dec. 2025 was NT$247.8 Mil.

Navicare Biotech Co's quarterly Accounts Payable declined from Jun. 2025 (NT$238.4 Mil) to Sep. 2025 (NT$217.7 Mil) but then increased from Sep. 2025 (NT$217.7 Mil) to Dec. 2025 (NT$247.8 Mil).

Navicare Biotech Co's annual Accounts Payable declined from Dec. 2023 (NT$311.3 Mil) to Dec. 2024 (NT$235.7 Mil) but then increased from Dec. 2024 (NT$235.7 Mil) to Dec. 2025 (NT$247.8 Mil).

Navicare Biotech Co Accounts Payable Related Terms

Navicare Biotech Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Navicare Biotech Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navicare Biotech Co Accounts Payable Chart

Navicare Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 232.62 296.15 311.27 235.73 247.81

Navicare Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 235.73 218.20 238.40 217.70 247.81
ROCO:8472
56GF Score
Navicare Biotech Co Ltd ROCO:8472
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Navicare Biotech Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$247.8 Mil mean?
Navicare Biotech Co (ROCO:8472) has a Accounts Payable of NT$247.8 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Navicare Biotech Co and its competitors.
Is Navicare Biotech Co's Accounts Payable too high?
Navicare Biotech Co's current Accounts Payable is NT$247.8 Mil. Overall, Navicare Biotech Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's Accounts Payable compare to AMZN and BABA?
Navicare Biotech Co's Accounts Payable of NT$247.8 Mil can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Retail - Cyclical company?
A good Accounts Payable depends on the Retail - Cyclical industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Navicare Biotech Co and its competitors. Navicare Biotech Co's current Accounts Payable is NT$247.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$44.45, compared to a current price of NT$68.20 — trading 53.4% above its estimated fair value. The current Accounts Payable is NT$247.8 Mil. Navicare Biotech Co's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current Accounts Payable is NT$247.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?

Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued. The current stock price of NT$68.20 is trading 53.4% above its estimated GF Value™ of NT$44.45. GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.

Key valuation signals for ROCO:8472:

  • Accounts Payable: NT$247.8 Mil
  • GF Value™: NT$44.45 vs. price of NT$68.20 (53.4% above fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Navicare Biotech Co Business Description

Address No. 100, Section 4, Citizen Avenue, 4th Floor, Da-an District, Taipei, TWN
Gomaji Corp Ltd is a local e-commerce company. The company connects merchants to consumers by offering goods and services at a discount.
56GF Score

Get the complete analysis for ROCO:8472

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$68.20
Price
NT$44.45
GF Value